INDIRECT COST IN NON-SMALL CELL LUNG CANCER (NSCLC): A SYSTEMATIC LITERATURE REVIEW

被引：0
|
作者：
Schmidt, E. [1 ]
Stanisic, S. [1 ]
Neumann, M. [1 ]
Walzer, S. [2 ]
机构：
[1] Analyt Int Inc, Lorrach, Germany
[2] F Hoffmann La Roche Pharmaceut AG, Basel, Switzerland
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
下载
收藏
页码：A271 / A271
页数：1
相关论文
共 50 条
  • [41] Gender Disparities in Non-Small Cell Lung Cancer: A Systematic Review
    Alsaadoun, Noor
    Kopciuk, Karen
    Hao, Desiree
    Riabowol, Karl
    Hollenbrg, Morley Hollenberg
    Bebb, Gwyn
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S352 - S353
  • [42] Systemic treatment and radiotherapy for patients with non-small cell lung cancer (NSCLC) and HIV infection - A systematic review
    Brandao, Mariana
    Durieux, Valerie
    Auprih, Masa
    Fozza, Alessandra
    Dauby, Nicolas
    Cuccia, Francesco
    Aspeslagh, Sandrine
    Verhaert, Marthe
    Giaj-Levra, Niccolo
    LUNG CANCER, 2023, 178 : 75 - 86
  • [43] Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence
    Attili, Ilaria
    Passaro, Antonio
    Pisapia, Pasquale
    Malapelle, Umberto
    de Marinis, Filippo
    CURRENT ONCOLOGY, 2022, 29 (01) : 255 - 266
  • [44] INTERVENTIONAL BRONCHOSCOPY FOR MALIGNANT AIRWAY OBSTRUCTION IN THE SETTING OF NON-SMALL CELL LUNG CANCER (NSCLC): A SYSTEMATIC REVIEW
    Umar, Zaryab
    Akbar, Usman
    Khalid, Saad
    Khan, Muhammad Aslam
    Abbas, Ramsha
    Ashfaq, Salman
    Ranat, Riki
    Foster, Allison
    Sandhu, Jasmine
    Ariyaratnam, Jonathan E.
    Parikh, Avish
    Hosna, Asma
    Haseeb-Ul-Rasool, Muhammad
    Lopez, Ricardo A.
    Trandafirescu, Theo D.
    Shostak, Eugene
    CHEST, 2023, 164 (04) : 5233A - 5234A
  • [45] Cost-effectiveness of immunotherapies for advanced squamous non-small cell lung cancer: a systematic review
    Cheng, Minyu
    Shao, Yanfei
    Li, Li
    Jiang, Menglao
    Song, Zhouye
    BMC CANCER, 2024, 24 (01)
  • [46] Cost-effectiveness of immunotherapies for advanced squamous non-small cell lung cancer: a systematic review
    Minyu Cheng
    Yanfei Shao
    Li Li
    Menglao Jiang
    Zhouye Song
    BMC Cancer, 24
  • [47] Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review
    Ding, Haiying
    Xin, Wenxiu
    Tong, Yinghui
    Sun, Jiao
    Xu, Gaoqi
    Ye, Ziqi
    Rao, Yuefeng
    PLOS ONE, 2020, 15 (09):
  • [48] A Systematic Review (SR) of Cost-effectiveness Analysis (CEA) of ALK Inhibitors (iALK) in Advance Non-small Cell Lung Cancer (NSCLC)
    Gabay, C.
    Solari, M. L.
    Moehler, T.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S247 - S248
  • [49] A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer
    Lange, A.
    Prenzler, A.
    Frank, M.
    Golpon, H.
    von der Schulenburg, Graf J-M
    ONKOLOGIE, 2013, 36 : 251 - 251
  • [50] Comparison between immunotherapy efficacy in early non-small cell lung cancer and advanced non-small cell lung cancer: a systematic review
    Yimin Wang
    Chuling Li
    Zimu Wang
    Zhaofeng Wang
    Ranpu Wu
    Ying Wu
    Yong Song
    Hongbing Liu
    BMC Medicine, 20
12345